Oliver Boix

ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancers

Immunotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer R Diamond, Valentina Boni, Emerson A Lim, Grzegorz Nowakowski, Raul Cordoba, Daniel Morillo, Ray Valencia, Isabelle Genvresse, Claudia Merz, Oliver Boix, Melanie M Frigault, Joy M Greer, Ahmed M Hamdy, Xin Huang, Raquel Izumi, Harvey Wong, Victor Moreno
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R Diamond, Sant P Chawla, Anthony W Tolcher, Patricia M LoRusso, Joseph P Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H J Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn Paul Lolkema
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (23) (2021)
Horst-Dieter Hummel, Peter Kufer, Carsten Grüllich, Ruth Seggewiss-Bernhardt, Barbara Deschler-Baier, Manik Chatterjee, Maria-Elisabeth Goebeler, Kurt Miller, Maria de Santis, Wolfgang Loidl, Christian Dittrich, Andreas K Buck, Constantin Lapa, Annette Thurner, Sabine Wittemer-Rump, Gökben Koca, Oliver Boix, Wolf-Dietrich Döcke, Ricarda Finnern, Helena Kusi, Antoinette Ajavon-Hartmann, Sabine Stienen, Cyrus Michael Sayehli, Bülent Polat, Ralf Christian Bargou
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy 13 (2) (2020)
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M Tsimberidou, Cynthia Ma, Sara A Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou, Matthias Ocker
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 11 (12) (2019)

Oliver Boix.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Oliver Boix